"10.1371_journal.pone.0087728","plos one","2014-01-31T00:00:00Z","Kazunori Tanaka; Takuya Kanno; Yoshiko Yanagisawa; Kaori Yasutake; Satoshi Inoue; Noriaki Hirayama; Joh-E Ikeda","NGP Biomedical Research Institute, Neugen Pharma Inc., Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; Wakunaga Pharmaceutical Co. Ltd., Akitakada, Hiroshima, Japan; Department of Molecular Life Sciences, Tokai University School of Medicine, Isehara, Kanagawa, Japan; Department of Molecular Neurology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; Apoptosis Research Centre, Childrenâ€™s Hospital of Eastern Ontario, Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada","Conceived and designed the experiments: KT TK JEI. Performed the experiments: KT TK YY KY SI NH. Analyzed the data: KT TK JEI. Contributed reagents/materials/analysis tools: KT TK YY KY SI NH JEI. Wrote the paper: KT TK JEI.","KT, TK, and KY are employees of Neugen Pharma Inc., Japan. YY was an employee of Neugen Pharma at the time this research was performed. JEI owns stocks or shares in Neugen Pharma. SI is an employee of Wakunaga Pharmaceutical Co.Ltd., Japan. WN1316 compound used in this study was developed by Neugen Pharma in collaboration with Wakunaga Pharmaceutical. This study is part of a patent application to be published (WO 2012/014699 A1: Therpeutic agent for neurological diseases). This does not alter the author's adherence to all the PLOS ONE policies on sharing data and materials.","2014","01","Kazunori Tanaka","KT",7,TRUE,3,6,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
